Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group - PubMed (original) (raw)

Randomized Controlled Trial

. 2009 Dec 15;115(24):5828-35.

doi: 10.1002/cncr.24667.

Affiliations

Randomized Controlled Trial

Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group

Howard M Katzenstein et al. Cancer. 2009.

Abstract

Background: The current study was conducted to determine whether amifostine is effective in reducing the toxicities associated with the administration of platinum-containing regimens in children with hepatoblastoma (HB).

Methods: Patients were enrolled on P9645 beginning in March of 1999. Patients who had stage I/II disease received treatment with 4 cycles of combined cisplatin, 5-fluorouracil, and vincristine (C5V) with or without amifostine. Patients who had stage III/IV disease were randomized to receive treatment with 6 cycles of either C5V with or without amifostine or carboplatin alternating with cisplatin (CC) with or without amifostine. Patients who were randomized to receive amifostine were given a dose of 740 mg/m2 intravenously over 15 minutes before each administration of a platinum agent.

Results: Eighty-two patients were considered in a special interim analysis of the incidence of toxicity. The disease outcome for patients who received amifostine was similar to the outcome for patients who did not receive amifostine (P=.22). The incidence of significant hearing loss (>40 dB) was similar for patients who did or did not receive amifostine (38% [14 of 37 patients] vs 38% [17 of 45 patients], respectively; P=.68). There were no differences in the incidence of renal or bone marrow toxicities evaluated. Patients who received amifostine had a higher incidence of hypocalcemia (5% vs 0.5%; P=.00006).

Conclusions: Amifostine in the doses and schedule used in this study failed to significantly reduce the incidence of platinum-induced toxicities in patients with HB.

Copyright (c) 2009 American Cancer Society.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Treatment schema for patients on COG P9645. CDDP=cisplatin, 5-FU=5-fluorouracil, VCR=vincristine CARBO=carboplatin, AMI=amifostine

Figure 2

Figure 2

Evaluation cohort

Figure 3

Figure 3

EFS of 184 patients who enrolled before 3/31/2003 and received chemotherapy by stratum of amifostine randomization. Adjusted p-value for the risk of an adverse event associated with amifostine = 0.22.

Comment in

Similar articles

Cited by

References

    1. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:96–99. - PubMed
    1. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991;9:2167–2176. - PubMed
    1. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050–1058. - PubMed
    1. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol. 2002;20:3438–3444. - PubMed
    1. Dall'Igna P, Cecchetto G, Dominici C, et al. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: a discouraging pilot study. Med Pediatr Oncol. 2001;36:332–334. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources